NEW HAVEN, Conn. – A leading cancer genetics expert has identified several significant barriers that prevent wider use of genetic testing in prostate cancer patients. These obstacles include a shortage of specialists and concerns about insurance coverage.
In an interview with Urology Times, Dr. Veda N. Giri outlined the challenges. She is a professor at Yale School of Medicine and directs the Cancer Genetics and Prevention Program at Yale Cancer Center.
One major issue is the limited number of genetic counselors. Dr. Giri stated that the high volume of patients has prompted a search for alternative counseling methods.
Financial concerns also create obstacles. While the out-of-pocket cost for genetic tests has dropped, insurance coverage remains inconsistent across the United States.
Dr. Giri also addressed the fear of insurance discrimination. She pointed to the Genetic Information Nondiscrimination Act (GINA). This law protects individuals from discrimination in health insurance and employment. However, GINA does not extend to life, disability, or long-term care insurance.
Dr. Giri emphasized that clinicians must discuss this gap with patients. This ensures patients can make informed decisions and prepare for potential financial impacts.
The barriers were detailed in a recent review article co-authored by Dr. Giri, published in EBioMedicine.
Related topics:
